{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:16Z","timestamp":1790959336447,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early identification of ATTRv amyloidosis disease onset is still often delayed due to the lack of validated biomarkers of this disease. Light chain neurofilament (NfL) have shown promising results in early diagnosis in this disease, but data is still needed, including with alternative measuring methods. Our aim was to study the levels of NfL measured by ELISA. Furthermore, interstitial matrix metalloproteinase type 1 (MMP-1) serum levels were measured as a potential new biomarker in ATTRv. Serum NfL and MMP-1 were measured using ELISA assays in 90 participants (29 ATTR-V30M patients, 31 asymptomatic V30M-<jats:italic>TTR<\/jats:italic> variant carriers and 30 healthy controls). Median NfL levels among ATTRv amyloidosis patients were significantly higher (116\u00a0pg\/mL vs 0\u00a0pg\/mL in both comparison groups). The AUC comparing ATTRv amyloidosis patients and asymptomatic carriers was 0.90 and the NfL concentration of 93.55\u00a0pg\/mL yielded a sensitivity of 79% and a specificity of 87%. NfL levels had a significant positive correlation with NIS values among patients. We found a negative significant correlation between eGFR and NfL levels. Finally, MMP1 levels were not different between groups. Evidence of NfL use for early diagnosis of ATTR-PN amyloidosis is growing. ELISA seems a reliable and available technique for it quantification. Decreased GFR could influence NfL plasma levels.<\/jats:p>","DOI":"10.1038\/s41598-023-50212-2","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:05:41Z","timestamp":1704445541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv)"],"prefix":"10.1038","volume":"14","author":[{"given":"Juan","family":"Gonz\u00e1lez-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Gragera-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Borrachero-Garro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garc\u00eda-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Barcel\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Manovel-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Ribot-Sans\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesly","family":"Ibarg\u00fcen-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gomila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mu\u00f1oz-Beamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Losada-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Cisneros-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"9","key":"50212_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima, Y. Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments. J. Neurol. Neurosurg. Psychiatry. 86(9), 1036\u20131043. https:\/\/doi.org\/10.1136\/jnnp-2014-308724 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"7","key":"50212_CR2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","volume":"62","author":"Y Ando","year":"2005","unstructured":"Ando, Y., Nakamura, M. & Araki, S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 62(7), 1057\u20131062 (2005).","journal-title":"Arch. Neurol."},{"issue":"4","key":"50212_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"Benson, M. D. & Kincaid, J. C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 36(4), 411\u2013423 (2007).","journal-title":"Muscle Nerve."},{"issue":"1","key":"50212_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o, I. et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 26(1), 3\u20139 (2019).","journal-title":"Amyloid."},{"issue":"Suppl 1","key":"50212_CR5","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams, D. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr. Opin. Neurol. 29(Suppl 1), S14-26 (2016).","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"50212_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ejhf.2113","volume":"23","author":"V Castiglione","year":"2021","unstructured":"Castiglione, V. et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 23(2), 217\u2013230 (2021).","journal-title":"Eur J Heart Fail."},{"issue":"16","key":"50212_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia, P. et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 42(16), 1554\u20131568 (2021).","journal-title":"Eur. Heart J."},{"issue":"3","key":"50212_CR8","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau, S. et al. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology. 96(3), e412\u2013e422 (2021).","journal-title":"Neurology."},{"issue":"1","key":"50212_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jns.12524","volume":"28","author":"V Loser","year":"2023","unstructured":"Loser, V. et al. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis\u2014A Swiss reference center experience. J. Peripher. Nerv. Syst. 28(1), 86\u201397 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"50212_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","volume":"28","author":"J Louwsma","year":"2021","unstructured":"Louwsma, J. et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 28(1), 50\u201355 (2021).","journal-title":"Amyloid."},{"issue":"6","key":"50212_CR11","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius, \u00c5. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 90(6), e518\u2013e524 (2018).","journal-title":"Neurology."},{"issue":"10","key":"50212_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14(10), 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"50212_CR13","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s13311-021-01136-0","volume":"18","author":"L Wieske","year":"2021","unstructured":"Wieske, L., Smyth, D., Lunn, M. P., Eftimov, F. & Teunissen, C. E. Fluid biomarkers for monitoring structural changes in polyneuropathies: Their use in clinical practice and trials. Neurotherapeutics. 18(4), 2351\u20132367 (2021).","journal-title":"Neurotherapeutics."},{"issue":"10","key":"50212_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1242\/dmm.028571","volume":"10","author":"D Martins","year":"2017","unstructured":"Martins, D., Moreira, J., Gon\u00e7alves, N. P. & Saraiva, M. J. MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. Dis. Model. Mech. 10(10), 1253\u20131260 (2017).","journal-title":"Dis. Model. Mech."},{"issue":"1","key":"50212_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1096\/fj.04-2022fje","volume":"19","author":"MM Sousa","year":"2005","unstructured":"Sousa, M. M., do Amaral, J. B., Guimar\u00e3es, A. & Saraiva, M. J. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J. 19(1), 124\u2013126 (2005).","journal-title":"FASEB J."},{"key":"50212_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando, Y. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet. J. Rare Dis. 8, 31 (2013).","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"50212_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia, L. F. et al. Plasma neurofilament light chain: An early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 27(2), 97\u2013102 (2020).","journal-title":"Amyloid."},{"issue":"4","key":"50212_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor, M. et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripher. Nerv. Syst. 24(4), 314\u2013319 (2019).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"5","key":"50212_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1055\/s-0039-1688977","volume":"39","author":"L Zhou","year":"2019","unstructured":"Zhou, L. Small fiber neuropathy. Semin. Neurol. 39(5), 570\u2013577 (2019).","journal-title":"Semin. Neurol."},{"key":"50212_CR20","first-page":"1","volume":"12","author":"M Sato","year":"2023","unstructured":"Sato, M. et al. Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis. Amyloid. 12, 1\u20132 (2023).","journal-title":"Amyloid."},{"issue":"2","key":"50212_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40520-021-02054-z","volume":"34","author":"A Ladang","year":"2022","unstructured":"Ladang, A. et al. Neurofilament light chain concentration in an aging population. Aging Clin. Exp. Res. 34(2), 331\u2013339 (2022).","journal-title":"Aging Clin. Exp. Res."},{"key":"50212_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104177","volume":"67","author":"KZ Revendova","year":"2022","unstructured":"Revendova, K. Z. et al. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels. Mult Scler Relat. Disord. 67, 104177 (2022).","journal-title":"Mult Scler Relat. Disord."},{"issue":"8","key":"50212_CR23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/brainsci11080980","volume":"11","author":"PM Ferraro","year":"2021","unstructured":"Ferraro, P. M. et al. Renal involvement in hereditary transthyretin amyloidosis: An italian single-centre experience. Brain Sci. 11(8), 980 (2021).","journal-title":"Brain Sci."},{"issue":"1","key":"50212_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00000441-198501000-00003","volume":"289","author":"M Skinner","year":"1985","unstructured":"Skinner, M. et al. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives. Am. J. Med. Sci. 289(1), 17\u201321 (1985).","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"50212_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson, J. L. S. et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ. Heart Fail. 11(2), e004000 (2018).","journal-title":"Circ. Heart Fail."},{"issue":"4","key":"50212_CR26","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s10072-021-05850-7","volume":"43","author":"M Luigetti","year":"2022","unstructured":"Luigetti, M. et al. Neurofilament light chain as a disease severity biomarker in ATTRv: Data from a single-centre experience. Neurol. Sci. 43(4), 2845\u20132848 (2022).","journal-title":"Neurol. Sci."},{"issue":"5","key":"50212_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/acn3.51355","volume":"8","author":"A Gauthier","year":"2021","unstructured":"Gauthier, A. et al. Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis. Ann. Clin. Transl. Neurol. 8(5), 1141\u20131150 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"50212_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016072118","volume":"118","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc. Natl. Acad. Sci. U.S.A. 118(9), e2016072118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"50212_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16070","volume":"31","author":"A Romano","year":"2024","unstructured":"Romano, A. et al. Serum neurofilament light chain: A promising early diagnostic biomarker for hereditary transthyretin amyloidosis?. Eur. J. Neurol. 31(1), e16070 (2024).","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"50212_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/brainsci12121708","volume":"12","author":"M Luigetti","year":"2022","unstructured":"Luigetti, M. et al. Serum inflammatory profile in hereditary transthyretin amyloidosis: Mechanisms and possible therapeutic implications. Brain Sci. 12(12), 1708 (2022).","journal-title":"Brain Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50212-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:08:33Z","timestamp":1704445713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50212-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50212"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50212-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"581"}}